(Sharecast News) - Denmark's Novo Nordisk said on Thursday that it has agreed to buy Akero Therapeutics - a clinical-stage company developing treatments for patients with serious metabolic diseases - for up to $5.2bn.
It noted that Akero's fibroblast growth factor 21 (FGF21) analogue efruxifermin (EFX) is a potentially best-in-class treatment...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE